|Security||GALE / Galena Biopharma, Inc. (363256108)|
|President and CEO||Stergiou Andelos M.|
|Institutional Shares||1,193,283 - 6.10%|
|Common Shares Outstanding||19,572,568 shares (as of 2018-06-30)|
|Institutional Value||$ 1,196,000 USD|
GALPW / Galena Biopharma, Inc. Warrants exp. 2017-12-21|
GALEW / Galena Biopharma, Inc. Warrants exp. 2018-09-18
Institutional Stock Ownership and Shareholders
Galena Biopharma, Inc. (NASDAQ:GALE) has 8 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,193,283 shares.
Largest shareholders include
CVI Investments, Inc., BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Investment Management, LLC, Spot Trading L.l.c., Spot Trading L.L.C, BlackRock Advisors LLC, Spot Trading L.l.c., Spot Trading L.L.C, and MetLife Securities, Inc.
Galena Biopharma, Inc. (NASDAQ:GALE) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|MetLife Securities, Inc||1,090||0||-100.00||0||0|
|BlackRock Investment Management, LLC||36,205||0||-100.00||70||0||-100.00|
|BlackRock Advisors LLC||5,302||10|
|BlackRock Institutional Trust Company, N.A.||0||219,939||0||427|
|ARXIS SECURITIES LLC||13,039||0||-100.00||25||0||-100.00|
|Spot Trading L.l.c.||Put||7,500||4|
|Spot Trading L.L.C||17||5,000||29,311.76||0||3|
|MetLife Securities, Inc||54||0|
|BlackRock Investment Management, LLC||708,015||36,205||-94.89||248||70||-71.77|
|BlackRock Institutional Trust Company, N.A.||4,398,909||0||-100.00||1,541||0||-100.00|
|Spot Trading L.L.C||Put||0||7,500||0||5|
|CVI Investments, Inc.||14,000,000||569,901||-95.93|
|BlackRock Fund Advisors||6,014,689||351,882||-94.15||2,107||683||-67.58|
|Spot Trading L.L.C||Call||13,100||0||-100.00||25||0||-100.00|
|Spot Trading L.l.c.||5,000||3|
|Integral Derivatives, LLC||Call||18,200||0||-100.00||5||0||-100.00|
|BlackRock Advisors LLC||106,061||0||-100.00||37||0||-100.00|
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Related News Stories
The company is undercapitalized. There is no way for the company to bring their products to approval and production without further massive dilution of the shareholders. Even under optimistic scenarios, the revenues are still many years away. The market is not excited about the products and the stock. That is likely to continue. Every significant rally in the stock should be sold. (1-2)
As our previous article indicated, we can only wonder why Net Element Inc. (NETE) would use MissionIR as its investor relations firm. After all MissionIR was recently fined and subject to a Cease and Desist order from the SEC. The SEC also said MissionIR “operated as a fraud upon investors and violated, and caused violations of, the anti-touting provisions of the federal securities law.” If I were the CEO of a public company, I’m not sure that is the kind of IR firm I would want representing me. (64-0)
Its been a week since we publicly raised questions about why Jon Najarian of CNBC had not filed any Form 4s relating to shares he claimed to have purchased in Net Element Inc. (NETE). It remains unclear to us why he still has not filed these forms as required by the SEC, but the more time that passes the more we are inclined to believe that he never actually purchased the shares. (352-1)
Selling drugs is a relationship business. It's best to do it in person. That is why, on a summer evening in 2012, Alec Burlakoff was out for dinner with Steven Chun, the owner of Sarasota Pain Associates. Burlakoff was a sales manager for Insys Therapeutics, an Arizona-based pharmaceutical company with only one branded product, a new and highly potent opioid painkiller called Subsys. Chun was a doctor who prescribed a lot of opioids. (16-0)
Insys Therapeutics paid millions of dollars to doctors. The company called it a “speaker program,” but prosecutors now call it something else: a kickback scheme. (16-0)
as of ET